Anlon Healthcare Ltd (AHCL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Anlon Healthcare Ltd on NSE and BSE, with an AI summary of each filing.
We have attached herewith link of Investor Call recording held on Tuesday, November 03, 2026. Kindly take the same on your record. Thank you.
Audio / Video · 04 Nov 2026, 1:24 am
Anlon Healthcare Releases Q2 FY27 Earnings Call Audio Recording Anlon Healthcare Limited announced the availability of the audio recording for its Q2 FY27 earnings conference call, conducted on 3rd Nov'26 for the quarter ended 30th Sep'26. In compliance with SEBI LODR Regulation 30, the company has hosted the audio recording on its official website (www.anlon.in) for investors and analysts.
We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Investor Presentation · 31 Oct 2026, 1:07 am
Anlon Healthcare Q2 FY27 Investor Presentation Highlights Strong Growth Anlon Healthcare reported consolidated Q2 FY27 revenue of ₹10,561.0 Lacs, up 102.3% YoY and 20.6% QoQ, with EBITDA rising 84.1% YoY to ₹2,524.1 Lacs (23.9% margin) and PAT surging 84.4% YoY to ₹1,717.8 Lacs (16.3% margin). H1 FY27 revenue reached ₹19,317.2 Lacs (+125.9% YoY) with PAT at ₹2,545.9 Lacs (+97.9% YoY). Growth is driven by core NSAID APIs, CDMO expansions (3 molecules), and recent acquisitions (Apiqo, Bizotic, Anlon Medicos), supported by ~1,200 MTPA upcoming capacity commissioning in Q1 FY28.
We have attached herewith Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. Kindly take the same on your record. Thank you.
Financial Result · 29 Oct 2026, 11:13 pm
We have attached herewith outcome of Board Meeting held on Thursday, October 29, 2026. Kindly take the same on your record. Thank you.
Outcome · 29 Oct 2026, 11:03 pm
Anlon Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 11:02 pm
Anlon Healthcare Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 10,561 (+102.3% YoY | +20.6% QoQ) ■ EBITDA: 2,524 (+84.1% YoY | +61.9% QoQ) ■ EBITDA Margin (%): 23.9 (-236 bps YoY | +610 bps QoQ) ■ PAT: 1,337 (+43.5% YoY | +100.6% QoQ) ■ EPS (INR): 0.32 (+77.8% YoY | +100.0% QoQ)
We have attached herewith announcement as per Reg. 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 29 Oct 2026, 10:43 pm
Anlon Healthcare Secures In-Principle Approval for Share Swap Preferential Issue Anlon Healthcare Limited received 'In-Principle' approval from both the NSE and BSE on 28th Oct'26 for the proposed issuance of 8,05,35,651 equity shares with a face value of Rs. 2 each. The allotment will be executed on a preferential basis pursuant to a proposed share swap under Chapter V of SEBI (ICDR) Regulations, 2018. The approvals were communicated via NSE letter no. NSE/LIST/56913 and BSE letter no. LOD/PREF/DA/FIP/1029/2026-27.
We have attached herewith invitation for investor earning call. Kindly take the same on your record. Thank you.
Intimation · 03 Nov 2026, 5:00 pm
Anlon Healthcare Schedules Q2 & H1 FY27 Earnings Call on 3rd Nov'26 Anlon Healthcare Limited will host its earnings conference call on 3rd Nov'26 at 05:00 PM IST to discuss its unaudited operational and financial results for the quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). The management will be represented by Chairman and Managing Director Punit Kumar Rasadia. Primary dial-in access is available via +91 22 6280 1488 and +91 22 7115 8869, alongside international toll-free numbers for the USA, UK, Singapore, and Hong Kong.
Anlon Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone and ....
Intimation · 29 Oct 2026, 5:30 am
Anlon Healthcare Board Meeting Scheduled for 29th Oct'26 Anlon Healthcare Limited has scheduled a meeting of its Board of Directors on 29th Oct'26 at its registered office. The board will consider and approve the unaudited standalone and consolidated financial results of the company for the quarter and half-year ended 30th Sep'26, along with the Auditor's Limited Review Report thereon.
ANLON HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2030 .
Intimation · 29 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 29 Oct 2026, 5:30 am
Outcome of Board Meeting of ANLON HEALTHCARE LIMITED
Outcome · 14 Oct 2026, 3:22 am
Anlon Healthcare Approves Preferential Issue of Convertible Warrants Worth Up to Rs 250 Crore The Board of Directors of Anlon Healthcare approved raising funds up to Rs 250 crore on 13th Oct'26 through a preferential issue of fully convertible equity warrants (face value Rs 2 each) for cash consideration. The warrants will be issued to four investors across promoters (Punitkumar Rasadia, Meet Vachhani) and public entities (Smart Horizon Capital Advisors, Ploutos Plus Consultant). Investors must pay 25% upfront, with the remaining 75% payable upon conversion into equity shares within an 18-month tenure. The warrant price and volume will be determined subsequently.
ANLON HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 13-Oct-2026 to consider Fund raising.
Intimation · 30 Sept 2026, 12:20 am
Anlon Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/10/2026 ,inter alia, to consider and approve to discuss and deliberate ....
Intimation · 30 Sept 2026, 12:14 am
Anlon Healthcare Board to Consider Expansion Plans and Fundraising on 13th Oct'26 Anlon Healthcare Limited's Board of Directors will meet on 13th Oct'26 to discuss and evaluate business expansion plans across domestic and overseas markets. The board will also deliberate on fundraising options in one or more tranches to finance these initiatives, exploring avenues including equity, debt, borrowings, hybrid instruments, or combinations thereof, subject to necessary regulatory and shareholder approvals.
To consider Fund Raising and other business matters
Intimation · 30 Sept 2026, 12:05 am
We have attached herewith intimation as per Reg. 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 25 Sept 2026, 12:23 am
Anlon Healthcare to Participate in Arihant Capital Bharat Connect Conference Anlon Healthcare Limited announced that its management will participate virtually in the "Bharat Connect Conference: Rising Stars 2026," organized by Arihant Capital, on 29th Sep'26 from 3:00 PM to 4:00 PM IST. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared or discussed during the investor interaction.
We have attached herewith intimation as per Reg. 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 21 Sept 2026, 8:40 pm
Anlon Healthcare Incorporates Nigerian Subsidiary to Expand West African Operations Anlon Healthcare Limited incorporated a new subsidiary, Anlon Healthcare Nigeria Limited, effective 20th Sep'26. The parent company subscribed to a 90% equity stake by acquiring 90 million shares of face value 1 Naira each for an aggregate cash consideration of 90 million Naira, against the entity's total paid-up capital of 100 million Naira. The new venture will engage in manufacturing, trading, and distributing APIs, bulk drugs, formulations, cosmetics, and medical devices, providing strategic market access across 16 Western African countries.
We have attached herewith announcement as per Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 21 Sept 2026, 8:32 pm
Anlon Healthcare Discloses Revised Preferential Issue Pricing and Allottee Details Following shareholder approval on 5th Sep'26 for acquiring 44.94% of Apiqo Organics and 47.41% of Bizotic Lifescience via a share swap, Anlon Healthcare issued revised preferential issue disclosures responding to exchange queries. Under SEBI ICDR norms, the preferential issue floor price is fixed at Rs.17.85 per share, matching the 90-day NSE VWAP and independent fair valuation dated 1st Sep'26. The company also disclosed ultimate beneficial ownership details across 26 proposed allottees and uploaded the compliance certificate from practicing company secretaries.
We have attached herewith clarification regarding price movement. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 17 Sept 2026, 5:37 pm
Anlon Healthcare Clarifies Price Movement Driven Entirely by Market Factors Anlon Healthcare responded on 17th Sep'26 to BSE and NSE surveillance inquiries regarding significant movement in its share price. The company clarified that it has no undisclosed, price-sensitive information or pending announcements that could impact trading behavior. Reaffirming strict compliance with Regulation 30 of SEBI Listing Regulations, management stated that recent price and volume movements are purely market-driven, influenced by prevailing market conditions, investor sentiment, and trading activity beyond the company's control.
The Exchange has sought clarification from Anlon Healthcare Ltd on September 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 16 Sept 2026, 11:11 pm
We have attached herewith intimation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 15 Sept 2026, 5:51 pm
Brickwork Ratings Assigns BWR BBB/Stable to Anlon Healthcare's Bank Facilities Brickwork Ratings assigned a long-term rating of BWR BBB/Stable to Anlon Healthcare Ltd.'s Rs. 23.60 Cr bank facilities on 15th Sep'26. The rating reflects strong operational growth, low leverage, and solid debt coverage, balanced against regulatory and competition risks. For FY26, operating revenue stood at Rs. 176.54 Cr with a PAT of Rs. 27.81 Cr and Tangible Net Worth of Rs. 209.77 Cr. Total Debt/TNW was healthy at 0.22x, supported by proceeds from its Rs. 121.03 Cr IPO completed in Aug'25.
Please find attached herewith Revised Proceedings of Annual General Meeting held on September 05, 2026
Annual General Meeting · 07 Sept 2026, 7:23 pm
We hereby attached herewith Voting Results and Scrutinizers'' Report for the Annual General Meeting held on September 05, 2026.
Annual General Meeting · 05 Sept 2026, 9:47 pm
Please find attached herewith Proceedings of Annual General Meeting held on September 05, 2026
Annual General Meeting · 05 Sept 2026, 7:52 pm
We have attached herewith corrigendum. Kindly take the same on your record. Thank you.
Annual General Meeting · 26 Aug 2026, 5:00 am
Anlon Healthcare Revises Preferential Share Allotment Details Anlon Healthcare issued a corrigendum to its 13th AGM notice, revising details for a preferential share issue. The issue price is set at Rs. 17.85 per share, based on a valuation report dated Aug 06, '26, which is above the SEBI-determined floor price of Rs. 17.78. Post-allotment, the promoter group's shareholding will decrease from 52.68% to 49.85%. Public shareholding will consequently increase from 47.32% to 50.15%. These revisions follow observations from the BSE and NSE regarding the preferential allotment application.
We have attached herewith Annual Report for the financial year 2025-2026. Kindly take the same on your record. Thank you.
Others (Uncategorized) · 15 Aug 2026, 5:26 am